Recruiting

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(17 sites)

United States

Call for Information (Investigational Site 0019), Aurora, Colorado

Call for Information (Investigational Site 0026), Boston, Massachusetts

Call for Information (Investigational Site 0031), New York, New York

Call for Information (Investigational Site 0070), Fargo, North Dakota

Call for Information (Investigational Site 0032), Cincinnati, Ohio

Call for Information (Investigational Site 0071), Sioux Falls, South Dakota

Call for Information (Investigational Site 0054), Dallas, Texas

Brazil

MSD Brasil, São Paulo

France

MSD France, Paris

Germany

MSD Sharp & Dohme GmbH, München

Israel

Merck Sharp & Dohme Co. Ltd., Hod HaSharon

Italy

MSD Italia S.r.l., Rome

Netherlands

Merck Sharp & Dohme BV, Haarlem

Portugal

Merck Sharp & Dohme Lda., Paço de Arcos

South Korea

MSD Korea LTD, Seoul

Sweden

MSD Sweden, Stockholm

United Kingdom

Merck Sharp & Dohme Ltd., London